|
Cytochrome P450 2C9 (CYP2C9), a member of the CYP2C enzyme subfamily, ranks amongst the most important drug metabolizing enzymes in humans. Human CYP2C9 has been shown to exhibit genetic polymorphism. In addition to the wild-type protein CYP2C9 *1, at least 32 single nucleotide polymorphisms (SNPs) have been reported within the coding region of the CYP2C9 gene producing the variant allozymes.〔(CYP2C9 allele nomenclature )〕 CYP2C9 *3 is one of them. CYP2C9 *3 reflects an Ile359-Leu (I359L) change in the amino acid sequence,〔 and have reduced catalytic activity compared with the wild type (CYP2C9 *1).〔Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA, The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism, Pharmacogenetics. 1996 Aug; 6(4):341–9〕 ==References== 〔 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「CYP2C9*3」の詳細全文を読む スポンサード リンク
|